Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Which fecal occult blood test is best to screen for colorectal cancer?

Nature Reviews Gastroenterology & Hepatology volume 6, pages 140–141 (2009)Cite this article

Abstract

Fecal immunochemical tests (FITs) for hemoglobin represent a major advance over guaiac-based fecal occult blood tests (GFOBTs) for colorectal cancer screening. FITs specifically detect human hemoglobin in stool samples, whereas GFOBTs only detect heme. Studies show that FITs increase the detection rates of cancer and advanced adenoma compared with early-generation GFOBTs, and do so without the unacceptably high number of colonoscopies that high-sensitivity GFOBTs generate. Also, FITs are simpler to use than GFOBTs, they improve rates of patient participation, and their cut-off points for positive versus negative tests can be modified. A large, Dutch, population-based, randomized controlled trial has compared the performance of a GFOBT and a FIT on an intention-to-screen basis. This study found that the FIT detected two-and-a-half times as many cancers and advanced adenomas as did the GFOBT, despite similar colonoscopy rates. The latest generation of FITs should replace traditional GFOBTs in two-step (test then colonoscopy) screening for colorectal cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Allison JE et al. (1996) A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med 334: 155–159

    Article  CAS  Google Scholar 

  2. Young GP and Allison J (2008) Screening for colorectal cancer. In Textbook of Gastroenterology, edn 5 170–182 (Eds Yamada T. et al.) Philadelphia: Lippincott Williams and Wilkins

    Google Scholar 

  3. Smith A et al. (2006) Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 107: 2152–2159

    Article  Google Scholar 

  4. Van Rossum LG et al. (2008) Random comparison of guaiac and immunochemical fecal occult blood test for colorectal cancer in a screening population. Gastroenterology 135: 82–90

    Article  Google Scholar 

  5. Nakajima M et al. (2003) Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case–control study. Br J Cancer 89: 23–28

    Article  CAS  Google Scholar 

  6. Cole SR et al. (2003) A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 10: 117–122

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GP Young is Professor of Gastroenterology at Flinders University, Director of the Flinders Centre for Cancer Prevention and Control, and Academic Head of Gastrointestinal Services at the Flinders Medical Centre in Adelaide, SA, and SR Cole is Principal Medical Scientist in the Bowel Health Service of the Repatriation General Hospital, Daw Park, SA, Australia.,

    Graeme P Young & Stephen R Cole

Authors
  1. Graeme P Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen R Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graeme P Young.

Ethics declarations

Competing interests

GP Young has declared an association with the following companies: Beckman Coulter, as a former consultant and recipient of grant/research support, Eiken, as a recipient of grant/research support, and Enterix, as a former consultant and recipient of grant/research support. SR Cole declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, G., Cole, S. Which fecal occult blood test is best to screen for colorectal cancer?. Nat Rev Gastroenterol Hepatol 6, 140–141 (2009). https://doi.org/10.1038/ncpgasthep1358

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1358

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing